To date, existing and emerging therapies for multiple sclerosis (MS) have been evaluated solely in adult patients. MS in children is being increasingly recognized, however, and optimization of pediatric MS care requires that promising new therapies be made available to children and adolescents. Banwell et al. highlight the immunological, clinical and practical factors that must be considered when introducing new MS therapies into the pediatric population.
- Brenda Banwell
- Amit Bar-Or
- Marc Tardieu